Navigation Links
ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens
Date:7/14/2009

HALIFAX, NS, July 14 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has entered into an agreement to exclusively license seven cancer antigens from Immunotope Inc., an antigen discovery company. These proprietary antigens specifically target breast, ovarian and prostate cancers. IVT will combine the proprietary antigens with its DepoVax(TM) delivery platform to develop DPX-0907, a therapeutic cancer vaccine. Within the next six months the company will fast-track DPX-0907 into Phase 1 clinical trials.

"Advanced-stage breast, ovarian and prostate cancers remain devastating and challenging diseases that urgently need treatment options, and we are excited to use Immunotope's antigens in our platform" said Dr. Randal Chase, president CEO of IVT. "This licensing agreement significantly advances our cancer immunotherapy capabilities and represents our continued commitment to developing our DepoVax(TM) technology within a robust clinical trial program."

"This agreement combines our antigen discovery expertise with IVT's product development capabilities and we are pleased to have our antigens become part of such an innovative vaccine candidate," said Ramila Philip, president and CSO of Immunotope Inc.

Under the license agreement, IVT has agreed to an up-front payment, as well as future milestone payments and royalties to Immunotope for use of the antigens. This licensing agreement replaces the acquisition of Immunotope agreement.

DPX-0907 is a novel vaccine because of its potential to create a depot at the injection site and cause a strong, rapid, long-lasting immune response that specifically targets cancer cells.

ImmunoVaccine Technologies is strengthening its innovative vaccine pipeline through licensing and strategic partnering to develop therapeutic cancer and infection disease vaccines. In 2008, Pfizer Animal Health licensed its proprietary DepoVax(TM) technology for two liv
'/>"/>

SOURCE ImmunoVaccine Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. ImmunoVaccine Technologies Partners with FIT Biotech to advance a therapeutic HIV vaccine
2. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
3. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
4. ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canadas Ability to Deal with Biological Threats
5. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
6. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
7. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
8. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
9. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
10. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
11. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., Nov. 24 IES (Nasdaq: ...and communications systems and services for the co...unced today that its commercial business group has...to install the electrical systems for the Level 4 ... U.S. Army Medical Research Institute of Infectiou...
(Date:11/24/2009)..., REYKJAVIK, Iceland, November 24 /PRNewswire-...) today announced that it has received notice from...ny,s common stock will be,suspended as of November...,Securities and Exchange Commission, which will re... unless the company files an appeal to the Nasdaq,...
(Date:11/24/2009)...EO, Calif., Nov. 24 Neur...company focused on developing and commercializing ...hat Anthony DiTonno, President and Chief Executive...al Piper Jaffray Health Care Conference, to be hel...in New York, New York. ,, Mr. DiTonno and Step...
(Date:11/24/2009)...E: HTL , TORONTO, Nov. 24 /PRNewswire-FirstCa...Calotto Capital Inc., a leading provider of advanc... research and fertility clinic markets, today repo...rd quarter ended September 30, 2009. , , Q3 20...ompared with $1.43 million in Q3 2008, - Gros...
Breaking Biology Technology:Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10
...FDA Offers Special Protocol Assessment for Reviroc... today,that it has successfully completed an End o...and Drug Administration (FDA). Reviroc is under,de...autologous graft in,bone marrow transplantations f... that the data from the completed phase II clinica...
...ZURICH, Switzerland, December 19 An exclusive lic...a drug delivery system for,lung infections in Cyst...the agreement, aRigen Pharmaceuticals Inc., Japan ...f Switzerland. The EMEA has already granted,orphan...e II clinical trial,will be initiated by Axentis P...
..., The Nano-Science Center at the University of Co...nding from the European Unions Seventh Framework P...to maintain and develop Europes leading position i...er is the first Danish research institution to be ...mme. , The goal of the research project is to exp...
Other Biology Technology:Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc 2Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections 2Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections 3
(Date:11/25/2009)...ters, police officers and ambulance workers faced ...er complex. They battled to save people from the c...kled fires and evacuated as many people as they co... people. And making their jobs even harder was the...s and their relatives jammed mobile networks with ...
(Date:11/25/2009)...t may be just as vital to your health as what you ...iological Studies. Their experiments in mice revea...of genes in the liverthe body,s metabolic clearing...y the body,s circadian clock as conventional wisdo...ivity of a large number of genes completely indepe...
(Date:11/24/2009)... and flabby arteries from collapsing have been tru...are no longer needed -- once the arteries are stre...tors had no choice but to leave them in place. , ...epartment of Biomedical Engineering has developed ...rugs where they,re needed, then dissolves. , "Ou...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3A coating for life 2Developmental drug may help bone fractures heal after radiation exposure 60527 1European Union Approves Corn Stack with Herculex RW and Roundup Ready 2 Traits for Food Feed Import and Processing 14688 1European Union Approves Corn Stack with Herculex RW and Roundup Ready 2 Traits for Food Feed Import and Processing 14688 2European Union Approves Corn Stack with Herculex RW and Roundup Ready 2 Traits for Food Feed Import and Processing 14688 3Professional HealthCare at Home Expands Services to Provide Licensed Hospice Care in Northern California 60524 1Professional HealthCare at Home Expands Services to Provide Licensed Hospice Care in Northern California 60524 2
...ion people die every year from respiratory disease...articular, an infection can be dangerous. What is ...s risk group as it is with younger people. The rea...e immune system is reduced. Why this is the case i... by the University of Bonn is now starting which a...
...Canadian research team surveying mercury contamina...States and southeastern Canada has identified five...ceed those established for human or wildlife healt...oxin in yellow perch and common loons, but it also...rds, and mammals. In addition to these hotspots in...
..., Medicare will pay for tens of thousands of heart...heir chests. Called ICDs or implantable cardiovert...ned to shock damaged hearts back into rhythm and s...s 300,000 Americans each year. , But a new study f...t from their ICDs, a large number won,t -- and a s...
Other Biology News:Fighting influenza & co. with 40,000 blood samples 2Fighting influenza & co. with 40,000 blood samples 3Hotspots of mercury contamination identified in eastern North America 2Are one-third of costly implanted heart devices unnecessary? New study suggests yes 2Are one-third of costly implanted heart devices unnecessary? New study suggests yes 3
11(R)-HETE from Cayman Chemical
PowerEase 500 Pre-Cast Gel System includes PowerEase Power Supply Temperature Monitoring Probe Xcell SureLock Mini-Cell and Xcell II Blot Module from Invitrogen
Goat Anti-TNF-R2 (L-20) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
MitoCapture Apoptosis Detection Kit from BioVision
Biology Products: